GSK Sets Sights On ViiV HIV Spin-Out In 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Andrew Witty said the company will explore the possibility of an IPO of a minority stake in ViiV, an HIV-centric joint venture with Pfizer and Shionogi, as the company continues to reshape its business.